PORTOS gene signature as a predictor of risk of adverse events after dose-escalated vs. lower-dose prostate radiation therapy in NRG/RTOG 0126. Five-year changes in urinary function and prostate ...

View all available purchase options and get full access to this article. Supported by Damon Runyon Foundation, V Foundation for Cancer Research, and Sabin Family Foundation (X.L.); NIH/NCI P30CA016672 ...

The Journal of Clinical Oncology podcast, hosted by Dr. Shannon Westin and Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of ...

How Should We Manage the Impact of Antimicrobial Resistance in Patients With Cancer? An Oncological and Infectious Disease Specialist Point of View ...

Multivariate adjusted analysis of 30-day complications and adverse events associated with radical and partial nephrectomy (reference group set as the post-pandemic cohort).

P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell ...

The article by Biller et al entitled “Comparison of PREMM5 and PREMMplus Risk Assessment Models to Identify Lynch Syndrome” (JCO Precision Oncology 10.1200/PO-24 ...

S2,3PSA% as a predictor of reclassification of 1st protocol biopsy on active surveillance for early-stage prostate cancer patients: From the PRIAS-JAPAN study. The nature of progression on long term ...

This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not include a full text component.

Safety profile of lutetium-177 in patients with impaired renal function: A retrospective analysis of adverse events in mCRPC treatment. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma A total of 121 patients (previous ICI-treated cohort, n = 31, and each of ...

If We Build It, Why They Do Not Come? An American College of Surgeons National Quality Improvement Collaborative to Understand Barriers to Completion of Cancer Treatment Study population consisted of ...